CN115485029A - 用于肝癌的miv-818/乐伐替尼组合疗法 - Google Patents

用于肝癌的miv-818/乐伐替尼组合疗法 Download PDF

Info

Publication number
CN115485029A
CN115485029A CN202180028332.9A CN202180028332A CN115485029A CN 115485029 A CN115485029 A CN 115485029A CN 202180028332 A CN202180028332 A CN 202180028332A CN 115485029 A CN115485029 A CN 115485029A
Authority
CN
China
Prior art keywords
lenvatinib
miv
cancer
liver
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028332.9A
Other languages
English (en)
Chinese (zh)
Inventor
F·欧伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB filed Critical Medivir AB
Publication of CN115485029A publication Critical patent/CN115485029A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180028332.9A 2020-04-15 2021-04-14 用于肝癌的miv-818/乐伐替尼组合疗法 Pending CN115485029A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE2050430-4 2020-04-15
SE2050430 2020-04-15
PCT/SE2021/050338 WO2021211039A1 (en) 2020-04-15 2021-04-14 Miv-818/lenvatinib combination therapy for liver cancer

Publications (1)

Publication Number Publication Date
CN115485029A true CN115485029A (zh) 2022-12-16

Family

ID=78084457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028332.9A Pending CN115485029A (zh) 2020-04-15 2021-04-14 用于肝癌的miv-818/乐伐替尼组合疗法

Country Status (13)

Country Link
US (1) US20240024342A1 (https=)
EP (1) EP4135849B1 (https=)
JP (1) JP7709456B2 (https=)
KR (1) KR20230003522A (https=)
CN (1) CN115485029A (https=)
AU (1) AU2021255043B9 (https=)
CA (1) CA3174940A1 (https=)
ES (1) ES3027841T3 (https=)
HR (1) HRP20250669T1 (https=)
HU (1) HUE071473T2 (https=)
PL (1) PL4135849T3 (https=)
TW (1) TW202200140A (https=)
WO (1) WO2021211039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
TW202444368A (zh) * 2023-03-30 2024-11-16 瑞典商米迪維艾克提伯拉公司 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151044A1 (en) * 2016-03-02 2017-09-08 Medivir Ab Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN110831597A (zh) * 2017-05-16 2020-02-21 卫材R&D管理有限公司 肝细胞癌的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ729118A (en) * 2014-08-25 2022-02-25 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
US11098002B2 (en) * 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151044A1 (en) * 2016-03-02 2017-09-08 Medivir Ab Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN110831597A (zh) * 2017-05-16 2020-02-21 卫材R&D管理有限公司 肝细胞癌的治疗

Also Published As

Publication number Publication date
HRP20250669T1 (hr) 2025-08-01
EP4135849A1 (en) 2023-02-22
JP2023522325A (ja) 2023-05-30
US20240024342A1 (en) 2024-01-25
EP4135849B1 (en) 2025-03-19
EP4135849A4 (en) 2024-04-17
WO2021211039A1 (en) 2021-10-21
ES3027841T3 (en) 2025-06-17
AU2021255043B2 (en) 2025-06-05
KR20230003522A (ko) 2023-01-06
HUE071473T2 (hu) 2025-09-28
PL4135849T3 (pl) 2025-07-14
JP7709456B2 (ja) 2025-07-16
AU2021255043A1 (en) 2022-11-03
EP4135849C0 (en) 2025-03-19
AU2021255043B9 (en) 2025-07-10
CA3174940A1 (en) 2021-10-21
TW202200140A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
KR102703122B1 (ko) 소라페닙 또는 레고라페닙과 트록사시타빈의 포스포라미데이트 전구약물의 병용 요법
JP7709456B2 (ja) 肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法
Momose et al. Trends in the treatment of advanced pancreatic cancer
Huang et al. Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE
HK40081068A (en) Miv-818/lenvatinib combination therapy for liver cancer
HK40040637B (zh) 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗
HK40040637A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40000353B (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40000353A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
AU2018234141A1 (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
BR112018067387B1 (pt) Uso de um agente terapêutico
TW202612702A (zh) 吡啶并［２，３－ｄ］嘧啶－２（１Ｈ）－酮類衍生物聯合用藥在治療和預防腫瘤疾病中的用途
Yamashita et al. Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced
de Souza Cancer drug toxicities and anaesthesia
WO2010019396A1 (en) Administration of glufosfamide for the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081068

Country of ref document: HK